Sugi Predict

Sugi Predict / Compounds / SCHEMBL407788

SCHEMBL407788

SCHEMBL407788

C[C@@](N)(Cc1ccccc1)C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 1/20 0.57
▸ TAAR1 Q96RJ0 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ BLM P54132 2/20 0.55
▸ MAPT P10636 3/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ CYP3A4 P08684 3/20 0.46
▸ RECQL P46063 3/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ USP2 O75604 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ FYN P06241 1/20 0.46
▸ POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL407787 1.00 SLC6A2 (0.57) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
SCHEMBL5268840 1.00 SLC6A2 (0.57) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
Hydrochloric Acid SCHEMBL28585467 0.98 SLC6A2 (0.55) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
Hydrochloric Acid SCHEMBL28585466 0.98 SLC6A2 (0.55) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
SCHEMBL7403762 0.93 PLA2G10 (0.53) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
SCHEMBL8935465 0.93 BLM (0.53) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
Hydrochloric Acid SCHEMBL27320071 0.87 BLM (0.47) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
SCHEMBL9515271 0.86 BLM (0.46) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
SCHEMBL122295 0.86 BLM (0.72) SLC6A2TAAR1SMN1; SMN2HIF1ABLM
SCHEMBL202327 0.86 BLM (0.72) SLC6A2TAAR1SMN1; SMN2HIF1ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-63123398-A — — None — — JP disclosed
JP-63157990-A — — None — — JP disclosed
JP-63160599-A — — None — — JP disclosed
JP-57186495-A — — None — — JP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-0668770-A4 — — 1995-09-27 — — EP disclosed
EP-0668770-A1 $g(a)-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY WARNER-LAMBERT COMPANY (US) 1995-08-30 — — EP disclosed
WO-1994009031-A1 ANALOGUES OF CHOLECYSTOKININ (30-33) CONTAINING AN ALPHA-SUBSTITUTED AMINOACID WARNER-LAMBERT COMPANY (US) 1994-04-28 — — WO disclosed
WO-1992019254-A1 α-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY WARNER-LAMBERT COMPANY (US) 1992-11-12 — — WO disclosed
JP-S63160599-A PRODUCTION OF L-ALPHA-METHYLPHENYLALANINES MITSUBISHI GAS CHEM CO INC 1988-07-04 — — JP disclosed
JP-S63157990-A PRODUCTION OF L-ALPHA-METHYLPHENYLALANINES MITSUBISHI GAS CHEM CO INC 1988-06-30 — — JP disclosed
JP-S63123398-A PRODUCTION OF L-ALPHA-METHYLPHENYLALANINES MITSUBISHI GAS CHEM CO INC 1988-05-27 — — JP disclosed
JP-S57186495-A PREPARATION OF L-ALPHA-METHYLPHENYLALANINE UBE IND LTD 1982-11-16 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET SLC6A2 3028/4885TAAR1 3372/4885SMN1; SMN2 4421/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET SLC6A2 3028/4885TAAR1 3372/4885SMN1; SMN2 4421/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET SLC6A2 3028/4885TAAR1 3372/4885SMN1; SMN2 4421/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET SLC6A2 3028/4885TAAR1 3372/4885SMN1; SMN2 4421/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET SLC6A2 3028/4885TAAR1 3372/4885SMN1; SMN2 4421/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 SLC6A2 3458/4885TAAR1 3753/4885SMN1; SMN2 4701/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 SLC6A2 3458/4885TAAR1 3753/4885SMN1; SMN2 4701/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET SLC6A2 3028/4885TAAR1 3372/4885SMN1; SMN2 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.